{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T04:18:48Z","timestamp":1768623528603,"version":"3.49.0"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Amiodarone-induced thyrotoxicosis (AIT) is a common complication of amiodarone therapy. Although permanent withdrawal of amiodarone is recommended due notably to the risk of worsening of tachyarrhythmias, some patients may require the reintroduction of amiodarone several months after normalizing their thyroid function. We, retrospectively, assessed the effects of 131I therapy to prevent recurrence of AIT in euthyroid patients requiring reintroduction of amiodarone.<\/jats:p>\n               <jats:sec>\n                  <jats:title>Subjects and methods<\/jats:title>\n                  <jats:p>Amiodarone was required in 10 cases of recurrent symptomatic paroxysmal atrial fibrillation (AF) and in 5 cases of ventricular tachycardia (VT) (M=12, F=3, mean age: 63\u00b114\u2009years). The underlying heart disease was dilated cardiomyopathy (n=4), ischaemic heart disease (n=4), hypertensive heart disease (n=2), arrhythmogenic right ventricular dysplasia (n=2) and valvulopathy (n=1). Two patients had idiopathic paroxysmal AF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A mean 131I dose of 579\u00b1183\u2009MBq was administered 34\u00b137\u2009months after the episode of AIT. Amiodarone was reintroduced in 14 of 15 patients after a mean interval of 103\u00b1261\u2009d. Fourteen patients developed definite hypothyroidism necessitating l-thyroxine but we observed no late recurrence of AIT. After a mean follow-up of 22\u00b116\u2009months, tachyarrhythmias were controlled in 12 of 14 patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>131I therapy appears to be an effective and safe approach to prevent the recurrence of AIT in a patient requiring the reintroduction of amiodarone for tachyarrhythmias.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1016\/j.eupc.2003.11.002","type":"journal-article","created":{"date-parts":[[2004,3,3]],"date-time":"2004-03-03T10:17:38Z","timestamp":1078309058000},"page":"169-174","source":"Crossref","is-referenced-by-count":17,"title":["Radioiodine ablation of the thyroid to prevent recurrence of amiodarone-induced thyrotoxicosis in patients with resistant tachyarrhythmias"],"prefix":"10.1093","volume":"6","author":[{"given":"Jean-Sylvain","family":"Hermida","sequence":"first","affiliation":[{"name":"Cardiology Department, H\u00f4pital Sud, Centre Hospitalier Universitaire, University Hospital a \u00a0 \u00a0 80054 Amiens Cedex, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Tcheng","sequence":"additional","affiliation":[{"name":"Cardiology Department, H\u00f4pital Sud, Centre Hospitalier Universitaire, University Hospital a \u00a0 \u00a0 80054 Amiens Cedex, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevieve","family":"Jarry","sequence":"additional","affiliation":[{"name":"Cardiology Department, H\u00f4pital Sud, Centre Hospitalier Universitaire, University Hospital a \u00a0 \u00a0 80054 Amiens Cedex, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronique","family":"Moullart","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Centre, University Hospital b \u00a0 \u00a0 Amiens, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Arlot","sequence":"additional","affiliation":[{"name":"Endocrinology Department, University Hospital c \u00a0 \u00a0 Amiens, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Luc","family":"Rey","sequence":"additional","affiliation":[{"name":"Cardiology Department, H\u00f4pital Sud, Centre Hospitalier Universitaire, University Hospital a \u00a0 \u00a0 80054 Amiens Cedex, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Delonca","sequence":"additional","affiliation":[{"name":"Cardiology Department, H\u00f4pital Sud, Centre Hospitalier Universitaire, University Hospital a \u00a0 \u00a0 80054 Amiens Cedex, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Schvartz","sequence":"additional","affiliation":[{"name":"Biophysics and Nuclear Medicine Unit, Jean Godinot Institute d \u00a0 \u00a0 Reims, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2004,1,1]]},"reference":[{"key":"2023122209323862400_b1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/0002-9343(85)90336-5","article-title":"Effect of long-term amiodarone therapy on thyroid hormone levels and thyroid function","volume":"78","author":"Borowski","year":"1985","journal-title":"Am J Med"},{"key":"2023122209323862400_b2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.7326\/0003-4819-101-1-28","article-title":"Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy","volume":"101","author":"Martino","year":"1984","journal-title":"Ann Intern Med"},{"key":"2023122209323862400_b3","first-page":"240","article-title":"The effects of amiodarone on the thyroid","volume":"22","author":"Martino","year":"2001","journal-title":"Endocr Rev"},{"key":"2023122209323862400_b4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1089\/105072501300176471","article-title":"The various effects of amiodarone on thyroid function","volume":"11","author":"Bogazzi","year":"2001","journal-title":"Thyroid"},{"key":"2023122209323862400_b5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/hrt.79.2.121","article-title":"Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy","volume":"79","author":"Newman","year":"1998","journal-title":"Heart"},{"key":"2023122209323862400_b6","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/PL00024613","article-title":"Surgical management of amiodarone-associated thyrotoxicosis: too risky or too effective?","volume":"22","author":"Hamoir","year":"1998","journal-title":"World J Surg"},{"key":"2023122209323862400_b7","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1161\/circ.105.11.1275","article-title":"Successful treatment of amiodarone-induced thyrotoxicosis","volume":"105","author":"Osman","year":"2002","journal-title":"Circulation"},{"key":"2023122209323862400_b8","first-page":"3305","article-title":"Amiodarone is not definitively contraindicated in patients having experienced hyperthyroidism","volume":"102","author":"Leenhardt","year":"2001","journal-title":"Circulation"},{"key":"2023122209323862400_b9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0002-9343(91)90187-3","article-title":"Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism","volume":"91","author":"Trip","year":"1991","journal-title":"Am J Med"},{"key":"2023122209323862400_b10","first-page":"333","article-title":"Health effects of therapeutic use of 131I in hyperthyroidism","volume":"44","author":"Pauwels","year":"2000","journal-title":"Q J Nucl Med"},{"key":"2023122209323862400_b11","first-page":"3611","article-title":"Radioiodine treatment of hyperthyroidism\u2014prognostic factors for outcome","volume":"86","author":"Allahabadia","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2023122209323862400_b12","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/jnci\/83.15.1072","article-title":"Cancer risk after iodine-131 therapy for hyperthyroidism","volume":"83","author":"Holm","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"2023122209323862400_b13","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jama.280.4.347","article-title":"Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group","volume":"280","author":"Ron","year":"1998","journal-title":"JAMA"},{"key":"2023122209323862400_b14","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/S0140-6736(98)12295-X","article-title":"Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study","volume":"353","author":"Franklyn","year":"1999","journal-title":"Lancet"}],"container-title":["EP Europace"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/6\/2\/169\/54757461\/europace_6_2_169.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/6\/2\/169\/54757461\/europace_6_2_169.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T11:53:16Z","timestamp":1703245996000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/6\/2\/169\/481882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1,1]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,1,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.eupc.2003.11.002","relation":{},"ISSN":["1532-2092","1099-5129"],"issn-type":[{"value":"1532-2092","type":"electronic"},{"value":"1099-5129","type":"print"}],"subject":[],"published-other":{"date-parts":[[2004,1]]},"published":{"date-parts":[[2004,1,1]]}}}